
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech is a promising company, with strong growth potential and a solid financial standing. Its preliminary financial results for 2025 show 3-5% YoY revenue growth, which is expected to increase to 13-17% in 2026. Additionally, the company has a diverse product portfolio that includes soft tissue repair and bone fusion products, which are in high demand in the surgical market. Furthermore, Sanara has secured a new contract with a major group purchasing organization, and plans to launch a new bone bioadhesive in 2027, further expanding its product offerings. Despite a recent net loss, the company's continuing operations have become profitable and management is focused on sustaining revenue growth and improving profitability in the future. With an EV/Revenue multiple of 3.0x and projected revenue for the next 12 months, Sanara MedTech's stock has a price objective of $36, making it a potential buy for investors.
Bears say
Sanara MedTech is facing financial challenges as the company has a high level of long-term debt compared to its available cash and borrowing capacity. Additionally, the company's revenue growth may be impacted in the near future as their key product, BIASURGE, received a contract from Vizient Inc. which will not take effect until January 1, 2026. Furthermore, the company's cash flows from operating activities are low and may not be able to support their operations in the near-term.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares